Morphological modulation of ovarian endometrioma with elagolix: a case report

Manish Maladkar; Nayesh Patani; Chitra Tekchandani; Rachana Patil

doi:10.18203/2320-1770.ijrcog20261297

Authors

Manish Maladkar Medical and Regulatory Affairs, Scientific Department, Aristo Pharmaceuticals Private Limited, Mumbai, Maharashtra, India
Nayesh Patani Department of Obstetrics and Gynaecology, Patani Maternity Gynaec and Nursing Home, Mumbai, Maharashtra, India
Chitra Tekchandani Scientific Department, Aristo Pharmaceuticals Private Limited, Mumbai, Maharashtra, India
Rachana Patil Scientific Department, Aristo Pharmaceuticals Private Limited, Mumbai, Maharashtra, India

DOI:

https://doi.org/10.18203/2320-1770.ijrcog20261297

Keywords:

Ovarian endometrioma, Elagolix, Morphology, Endometriosis

Abstract

Ovarian endometrioma is a common manifestation of endometriosis, an estrogen-dependent inflammatory disorder associated with chronic pelvic pain and dysmenorrhea in women of reproductive age. Although surgical cystectomy is often effective, it may compromise ovarian reserve which is a significant concern, particularly in young women, highlighting the need for effective medical alternatives. We report a rare case of non-surgical management of a large ovarian endometrioma using the oral gonadotropin-releasing hormone (GnRH) antagonist, Elagolix. A 21-year-old unmarried woman presented with severe dysmenorrhea and lower abdominal pain, and ultrasonography revealed a right ovarian endometrioma. She was initiated treatment with Elagolix 150 mg once daily. The patient experienced significant symptomatic relief with marked reduction in pain scores and no notable hypoestrogenic adverse effects. Follow-up imaging at week 10 demonstrated morphological changes within the cyst suggestive of necrotic transformation and reduced endometrial cell viability indicating inhibition of disease progression. This case highlights the role of individualized, dose-dependent hormonal modulation with Elagolix as a non-surgical option for managing ovarian endometriomas, achieving both clinical and radiological improvement with fertility-preservation.

Metrics

Metrics Loading ...

References

Macer ML, Taylor HS. Endometriosis and Infertility. Obstet Gynecol Clin North Am. 2012;39(4):535-49. DOI: https://doi.org/10.1016/j.ogc.2012.10.002

Lamceva J, Uljanovs R, Strumfa I. The Main Theories on the Pathogenesis of Endometriosis. Int J Mol Sci. 2023;24(5):4254. DOI: https://doi.org/10.3390/ijms24054254

Zondervan KT, Becker CM, Missmer SA. Endometriosis. Longo DL, editor. N Engl J Med. 2020;382(13):1244-56. DOI: https://doi.org/10.1056/NEJMra1810764

Archer DF, Soliman AM, Agarwal SK, Taylor HS. Elagolix in the treatment of endometriosis: impact beyond pain symptoms. Clin Med Insights Reprod Health. 2020;14:2633494120964517. DOI: https://doi.org/10.1177/2633494120964517

Alborzi S, Zahiri Sorouri Z, Askari E, Poordast T, Chamanara K. The success of various endometrioma treatments in infertility: A systematic review and meta-analysis of prospective studies. Reprod Med Biol. 2019;18(4):312-22. DOI: https://doi.org/10.1002/rmb2.12286

Working group of ESGE, ESHRE, and WES; Saridogan E, Becker CM, Feki A, Grimbizis GF, Hummelshoj L, Keckstein J, et al. Recommendations for the surgical treatment of endometriosis-part 1: ovarian endometrioma. Gynecol Surg. 2017;14(1):27. DOI: https://doi.org/10.1186/s10397-017-1029-x

Ünlü C, Yıldırım G. Ovarian cystectomy in endometriomas: Combined approach. J Turk Ger Gynecol Assoc. 2014;15(3):177-89. DOI: https://doi.org/10.5152/jtgga.2014.1111

Miller C. The Endometrioma Treatment Paradigm When Fertility Is Desired: A Systematic Review. J Minim Invasive Gynecol. 2020;28. DOI: https://doi.org/10.1016/j.jmig.2020.11.020

Văduva CC, Dîră L, Boldeanu L, Șerbănescu MS, Carp-Velișcu A. A Narrative Review Regarding Implication of Ovarian Endometriomas in Infertility. Life (Basel). 2025;15(2):161. DOI: https://doi.org/10.3390/life15020161

Hoffman BL. Williams Gynecology. McGraw-Hill. 2017.

Vercellini P, Buggio L, Frattaruolo MP, Borghi A, Dridi D, Somigliana E. Medical treatment of endometriosis-related pain. Best Pract Res Clin Obstet Gynaecol. 2018;51:68-91. DOI: https://doi.org/10.1016/j.bpobgyn.2018.01.015

Lee J, Park HJ, Yi KW. Dienogest in endometriosis treatment: A narrative literature review. Clin Exp Reprod Med. 2023;50(4):223-9. DOI: https://doi.org/10.5653/cerm.2023.06128

Surrey ES. GnRH agonists in the treatment of symptomatic endometriosis: a review. F S Rep. 2022;4(2 Suppl):40-5. DOI: https://doi.org/10.1016/j.xfre.2022.11.009

Lamb YN. Elagolix: First Global Approval. Drugs. 2018;78(14):1501-8. DOI: https://doi.org/10.1007/s40265-018-0977-4

Wang JY, Zhang Y, Ding J. Oral Gonadotropin-Releasing Hormone Antagonists in the Treatment of Endometriosis: Advances in Research. J Clin Med Res. 2025;17(6):299-308. DOI: https://doi.org/10.14740/jocmr6236

Leyland N, Estes SJ, Lessey BA, Advincula AP, Taylor HS. A Clinician’s Guide to the Treatment of Endometriosis with Elagolix. J Women’s Health. 2021;30(4):569-78. DOI: https://doi.org/10.1089/jwh.2019.8096

Taylor HS, Giudice LC, Lessey BA, Abrao MS, Kotarski J, Archer DF, et al. Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist. N Engl J Med. 2017;377(1):28-40. DOI: https://doi.org/10.1056/NEJMoa1700089

Surrey E, Taylor HS, Giudice L, Lessey BA, Abrao MS, Archer DF, et al. Long-Term Outcomes of Elagolix in Women With Endometriosis: Results From Two Extension Studies. Obstet Gyneco. 2018;132(1):147-60. DOI: https://doi.org/10.1097/AOG.0000000000002675

Zhao Y, Gong P, Chen Y, Nwachukwu JC, Srinivasan S, Ko C, et al. Dual suppression of estrogenic and inflammatory activities for targeting of endometriosis. Sci Transl Med. 2015;7(271):271-9. DOI: https://doi.org/10.1126/scitranslmed.3010626

Yılmaz Hanege B, Güler Çekıç S, Ata B. Endometrioma and ovarian reserve: effects of endometriomata per se and its surgical treatment on the ovarian reserve. Facts Views Vis Obgyn. 11(2):151-7.